HCPLive

Role of Omega-3 in Secondary Prevention of CVD Questioned

Thursday, April 12 (HealthDay News) -- Sang Mi Kwak, M.D., from the Center for Cancer Prevention and Detection in Ilsan, South Korea, and colleagues conducted a meta-analysis of randomized, double-blind, placebo-controlled trials to investigate the efficacy of eicosapentaenoic acid and docosahexaenoic acid in the secondary prevention of CVD. The final analyses included 14 trials involving 20,485 patients with a history of CVD.

The researchers found that consuming omega-3 fatty acid supplements was not associated with a significantly reduced risk of overall cardiovascular events (relative risk [RR], 0.99), or with all-cause mortality, sudden cardiac death, myocardial infarction, congestive heart failure, or transient ischemic attack and stroke. The slight reduction in cardiovascular death (RR, 0.91) did not persist when a methodologically flawed study was excluded from the analyses. No significant preventive effect was seen in any of the subgroups analyzed.

"Our meta-analysis showed insufficient evidence of a secondary preventive effect of omega-3 fatty acid supplements against overall cardiovascular events among patients with a history of cardiovascular disease," the authors write.

The majority of the trials included in the study were funded by pharmaceutical companies.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

For patients with a history of cardiovascular disease, evidence is lacking for a secondary preventive effect of omega-3 fatty acid supplements, according to a meta-analysis published online April 9 in the Archives of Internal Medicine.

Copyright © 2012 HealthDay. All rights reserved.

Most Popular

Recommended Reading

Although the relationship between pain and spatial representation is unclear, a study published in Current Biology took steps in understanding how pain is activated in the brain and raised the possibility of reducing the sensation.
Working in an emergency room setting in the United States, in almost all circumstances provides doctors with at least most of the major needs they require to do their jobs on a daily basis. One organization is working to bring those basic needs to hospitals throughout Latin America.
Discontinuing the use of cholesterol-lowering statins in terminally ill patients may improve their quality of life, according to a new study published online March 23 in JAMA Internal Medicine.

A physician/pharmacist collaborative model can improve mean blood pressure (BP), according to a study published online March 24 in Circulation: Cardiovascular Quality and Outcomes.

$vAR$